![](https://www.prospertrading.com/wp-content/uploads/2019/03/shutterstock_713377621-961x649.jpg)
Lexicon Pharmaceuticals (LXRX) rallied strongly today after the European Medicines Agency’s Committee for Medicinal Product for Human Use gave LXRX’s Zynquista a positive mention. Zynquista is a joint development between Lexicon and Sanofi. Zynquista’s application for approval in the United States and Europe has been accepted and is currently under review. Here’s a recap.